| Dg Related Services | |
|
139 E Mcclellan Ave, Livingston, NJ 07039-1320 | |
| (973) 436-0895 | |
| Not Available |
| Full Name | Dg Related Services |
|---|---|
| Type | Facility |
| Speciality | Speech-language Pathologist |
| Location | 139 E Mcclellan Ave, Livingston, New Jersey |
| Accepts Medicare Assignments | Does not participate in Medicare Program. The facility may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1295514131 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 235Z00000X | Speech-language Pathologist | (* (Not Available)) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dg Related Services 139 E Mcclellan Ave, Livingston, NJ 07039-1320 Ph: (973) 436-0895 | Dg Related Services 139 E Mcclellan Ave, Livingston, NJ 07039-1320 Ph: (973) 436-0895 |
News Archive
LogLogic®, the leader in log and security management solutions, and the Ponemon Institute, a privacy and information management research firm, today announced results of a national survey of healthcare IT security professionals that shows patients may be surrendering their privacy as the $2.5 trillion medical industry – prompted by federal stimulus funding – pushes to accelerate the pace of digitizing health information records.
The U.S. FDA announced today that they would add additional safety warnings to the labels on statins, a class of drugs that lower cholesterol. Statins – with brand names Lipitor, Crestor and Zocor work by inhibiting the enzyme that plays a big part in the liver's production of cholesterol.
Generex Biotechnology Corporation today announced that its wholly-owned subsidiary, Antigen Express, Inc., has been granted a United States patent on AE37, its lead immunotherapeutic vaccine. While Antigen Express has a strong intellectual property foundation on all Ii-Key technology, this is the first "composition of matter" patent to be issued relating to one of their development products.
Resverlogix Corp. ("Resverlogix" or the "Company") announced today that it has begun dosing patients in its US Phase 2 clinical trial lead by Cleveland Clinic. This trial will examine RVX-208, Resverlogix's oral small molecule therapy for the treatment of atherosclerosis, in patients with stable coronary artery disease (CAD).
› Verified 5 days ago
Carrie Leshin, SPEECH-LANGUAGE PATH Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 8 Cyprus Ln, Livingston, NJ 07039 Phone: 917-538-3687 | |
Communication Exchange Llc Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 316 Eisenhower Pkwy, 201, Livingston, NJ 07039 Phone: 973-420-0992 | |
Pamela Block, MA, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 12 Cherry Hill Rd, Livingston, NJ 07039 Phone: 973-992-0042 | |
Mrs. Lisa Ann Serviss, MA, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 43 Cobblewood Rd, Livingston, NJ 07039 Phone: 973-868-2955 | |
Mrs. Deanna Goldstein, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 8 Princeton Rd, Livingston, NJ 07039 Phone: 973-493-4567 | |
Shari Grey, SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 66 W Mount Pleasant Ave, 203, Livingston, NJ 07039 Phone: 973-994-4468 Fax: 973-994-4412 | |
Jaclyn Goldstein, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 8 Burlington Rd, Livingston, NJ 07039 Phone: 973-650-3271 |